Movement Alert｜Moderna, Inc. Falls 4.85% in Regular Trading, Profit-Taking Persists Amid Post-Cancer Vaccine Surge Repricing

Market Focus

Yesterday

On August 26, Moderna, Inc. declined 4.85% in regular trading, trading at $149.49/share, with turnover of $375 million. The stock remains in a highly volatile repricing phase following its historic 177% single-day surge triggered by positive Phase III trial results for its personalized mRNA cancer vaccine intismeran autogene, co-developed with Merck.

Despite multiple Wall Street upgrades — including Wolfe Research upgrading to peer perform, Barclays raising its target from $48 to $125, Bank of America lifting to $170, and Jefferies to $150 — the stock continues to face profit-taking pressure. Notably, Barclays' $125 target and the analyst consensus mean target of $96.47 remain well below the current trading price, suggesting short-term valuation is stretched. Options market implied volatility sits at the 99.6th percentile, reflecting extreme uncertainty as bulls and bears actively contest fair value during the post-breakthrough repricing window.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://nz.tigermarketb.com/news/1154072566"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154072566\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1154072566?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-26 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154072566","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Moderna, Inc. Falls 4.85% in Regular Trading, Profit-Taking Persists Amid Post-Cancer Vaccine Surge Repricing","media":"Market Focus","content":"<p><p>On August 26, Moderna, Inc. declined 4.85% in regular trading, trading at $149.49/share, with turnover of $375 million. The stock remains in a highly volatile repricing phase following its historic 177% single-day surge triggered by positive Phase III trial results for its personalized mRNA cancer vaccine intismeran autogene, co-developed with Merck.</p><p>Despite multiple Wall Street upgrades — including Wolfe Research upgrading to peer perform, Barclays raising its target from $48 to $125, Bank of America lifting to $170, and Jefferies to $150 — the stock continues to face profit-taking pressure. Notably, Barclays' $125 target and the analyst consensus mean target of $96.47 remain well below the current trading price, suggesting short-term valuation is stretched. Options market implied volatility sits at the 99.6th percentile, reflecting extreme uncertainty as bulls and bears actively contest fair value during the post-breakthrough repricing window.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Moderna, Inc. Falls 4.85% in Regular Trading, Profit-Taking Persists Amid Post-Cancer Vaccine Surge Repricing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Moderna, Inc. Falls 4.85% in Regular Trading, Profit-Taking Persists Amid Post-Cancer Vaccine Surge Repricing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-26 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 26, Moderna, Inc. declined 4.85% in regular trading, trading at $149.49/share, with turnover of $375 million. The stock remains in a highly volatile repricing phase following its historic 177% single-day surge triggered by positive Phase III trial results for its personalized mRNA cancer vaccine intismeran autogene, co-developed with Merck.</p><p>Despite multiple Wall Street upgrades — including Wolfe Research upgrading to peer perform, Barclays raising its target from $48 to $125, Bank of America lifting to $170, and Jefferies to $150 — the stock continues to face profit-taking pressure. Notably, Barclays' $125 target and the analyst consensus mean target of $96.47 remain well below the current trading price, suggesting short-term valuation is stretched. Options market implied volatility sits at the 99.6th percentile, reflecting extreme uncertainty as bulls and bears actively contest fair value during the post-breakthrough repricing window.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1154072566","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154072566","pubTimestamp":1787751352,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 26, Moderna, Inc. declined 4.85% in regular trading, trading at $149.49/share, with turnover of $375 million. The stock remains in a highly volatile repricing phase following its historic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"走势警报|Moderna, Inc. 常规交易下跌 4.85%，癌症疫苗重新定价后获利回吐持续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"On August 26, Moderna, Inc. declined 4.85% in regular trading, trading at $149.49/share, with turnover of $375 million. The stock remains in a highly volatile repricing phase following its historic 177% single-day surge triggered by positive Phase III trial results for its personalized mRNA cancer vaccine intismeran autogene, co-developed with Merck.Despite multiple Wall Street upgrades — including Wolfe Research upgrading to peer perform, Barclays raising its target from $48 to $125, Bank of America lifting to $170, and Jefferies to $150 — the stock continues to face profit-taking pressure. Notably, Barclays' $125 target and the analyst consensus mean target of $96.47 remain well below the current trading price, suggesting short-term valuation is stretched. Options market implied volatility sits at the 99.6th percentile, reflecting extreme uncertainty as bulls and bears actively contest fair value during the post-breakthrough repricing window.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}